PT - JOURNAL ARTICLE AU - Aikou Okamoto AU - Rosalind M. Glasspool AU - Seiji Mabuchi AU - Noriomi Matsumura AU - Hiroyuki Nomura AU - Hiroaki Itamochi AU - Masashi Takano AU - Tadao Takano AU - Nobuyuki Susumu AU - Daisuke Aoki AU - Ikuo Konishi AU - Alan Covens AU - Jonathan Ledermann AU - Delia Mezzazanica AU - Christopher Steer AU - David Millan AU - Iain A. McNeish AU - Jacobus Pfisterer AU - Sokbom Kang AU - Laurence Gladieff AU - Jane Bryce AU - Amit Oza TI - Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary AID - 10.1097/IGC.0000000000000289 DP - 2014 Nov 01 TA - International Journal of Gynecologic Cancer PG - S20--S25 VI - 24 IP - Supp 3 4099 - http://ijgc.bmj.com/content/24/Supp_3/S20.short 4100 - http://ijgc.bmj.com/content/24/Supp_3/S20.full SO - Int J Gynecol Cancer2014 Nov 01; 24 AB - Abstract Clear cell carcinoma of the ovary (CCC) is a histologic subtype of epithelial ovarian cancer with a distinct clinical behavior. There are marked geographic differences in the prevalence of CCC. The CCC is more likely to be detected at an early stage than high-grade serous cancers, and when confined within the ovary, the prognosis is good. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. Cytoreductive surgery should be performed for patients with stage II, III, or IV disease. An international phase III study to compare irinotecan/cisplatin and paclitaxel/carboplatin as adjuvant chemotherapy for stage IIV CCC has completed enrollment (GCIG/JGOG3017). Considering the frequent PIK3CA mutation in CCC, dual inhibitors targeting PI3K, AKT in the mTOR pathway, are promising. Performing these trials and generating the evidence will require considerable international collaboration.